The incidence and severity of nausea and vomiting are reduced with moderate-dose administration of Hexalen®
capsules. In 2 clinical studies of single-agent Hexalen®
capsules utilizing a moderate, intermittent dose and schedule, only 1 patient (1%) discontinued Hexalen® capsules due to severe nausea and vomiting.
Neurotoxicity
Peripheral neuropathy and central nervous system symptoms (mood disorders, disorders of consciousness, ataxia, dizziness, vertigo) have been reported.